ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
ImmunityBio (IBRX) announced results from its Anktiva clinical program in non-small cell lung cancer based on two studies, ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with increased risk of depressive disorder (DD) ...
News-Medical.Net on MSN
Elevated neutrophil-to-lymphocyte ratio linked to depression and suicide risk
An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with increased risk of depressive disorder (DD) ...
High immune inflammation detected through simple blood tests is tied to a 57% higher risk of depression and a 56% higher risk ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...
ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug ...
Meta-analysis shows neutrophil to lymphocyte ratio is associated with higher risk and progression of diabetic nephropathy, ...
Elevated neutrophil-to-lymphocyte ratio is linked to diabetic nephropathy risk and progression. Learn more about its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback